Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Jun 15, 2026; 18(6): 117582
Published online Jun 15, 2026. doi: 10.4251/wjgo.v18.i6.117582
Published online Jun 15, 2026. doi: 10.4251/wjgo.v18.i6.117582
Table 6 Comparison of features between the training and validation sets, mean ± SD/n (%)
| Variables | Total (n = 200) | Test (n = 60) | Train (n = 140) | Statistic | P value |
| Neutrophil | 3.91 ± 2.32 | 4.21 ± 3.06 | 3.78 ± 1.92 | t = 1.00 | 0.320 |
| Lymphocyte | 1.38 ± 0.59 | 1.40 ± 0.69 | 1.37 ± 0.54 | t = 0.35 | 0.724 |
| PD-L1 expression | χ2 = 0.12 | 0.732 | |||
| CPS < 5 | 87 (43.50) | 25 (41.67) | 62 (44.29) | ||
| CPS ≥ 5 | 113 (56.50) | 35 (58.33) | 78 (55.71) | ||
| MMR status | χ2 = 1.20 | 0.274 | |||
| pMMR | 168 (84.00) | 53 (88.33) | 115 (82.14) | ||
| dMMR | 32 (16.00) | 7 (11.67) | 25 (17.86) | ||
| CAR | χ2 = 0.00 | 1.000 | |||
| High | 80 (40.00) | 24 (40.00) | 56 (40.00) | ||
| Low | 120 (60.00) | 36 (60.00) | 84 (60.00) | ||
| Sex | χ2 = 0.63 | 0.426 | |||
| Female | 75 (37.50) | 20 (33.33) | 55 (39.29) | ||
| Male | 125 (62.50) | 40 (66.67) | 85 (60.71) | ||
| Age | χ2 = 0.58 | 0.448 | |||
| < 60 years | 78 (39.00) | 21 (35.00) | 57 (40.71) | ||
| ≥ 60 years | 122 (61.00) | 39 (65.00) | 83 (59.29) | ||
| BMI | χ2 = 1.73 | 0.189 | |||
| < 25 | 166 (83.00) | 53 (88.33) | 113 (80.71) | ||
| ≥ 25 | 34 (17.00) | 7 (11.67) | 27 (19.29) | ||
| CEA | χ2 = 0.01 | 0.925 | |||
| < 3 | 79 (39.50) | 24 (40.00) | 55 (39.29) | ||
| ≥ 3 | 121 (60.50) | 36 (60.00) | 85 (60.71) | ||
| CA199 | χ2 = 2.76 | 0.097 | |||
| < 37 | 126 (63.00) | 43 (71.67) | 83 (59.29) | ||
| ≥ 37 | 74 (37.00) | 17 (28.33) | 57 (40.71) | ||
| ECOG PS | χ2 = 0.70 | 0.403 | |||
| 0 | 72 (36.00) | 19 (31.67) | 53 (37.86) | ||
| 1 | 128 (64.00) | 41 (68.33) | 87 (62.14) | ||
| Staging | χ2 = 0.16 | 0.687 | |||
| III | 91 (45.50) | 26 (43.33) | 65 (46.43) | ||
| IV | 109 (54.50) | 34 (56.67) | 75 (53.57) | ||
| Differentiation | χ2 = 0.26 | 0.607 | |||
| Poorly/undifferentiated | 180 (90.00) | 55 (91.67) | 125 (89.29) | ||
| Medium/high | 20 (10.00) | 5 (8.33) | 15 (10.71) | ||
| Site | χ2 = 0.04 | 0.838 | |||
| Gastric and esophageal binding | 58 (29.00) | 18 (30.00) | 40 (28.57) | ||
| Stomach | 142 (71.00) | 42 (70.00) | 100 (71.43) | ||
| Peritoneal metastasis | χ2 = 0.17 | 0.679 | |||
| No | 157 (78.50) | 46 (76.67) | 111 (79.29) | ||
| Yes | 43 (21.50) | 14 (23.33) | 29 (20.71) | ||
| Liver metastasis | χ2 = 0.20 | 0.655 | |||
| No | 156 (78.00) | 48 (80.00) | 108 (77.14) | ||
| Yes | 44 (22.00) | 12 (20.00) | 32 (22.86) | ||
| EBV status | χ2 = 0.06 | 0.802 | |||
| No-infect | 187 (93.50) | 57 (95.00) | 130 (92.86) | ||
| infect | 13 (6.50) | 3 (5.00) | 10 (7.14) |
- Citation: Mei S, Ye ML, Hao QL, Li GC, Yao ZY, Wang HY. Prognostic significance of baseline C-reactive protein/albumin ratio for long-term outcomes in advanced gastric cancer under immunochemotherapy. World J Gastrointest Oncol 2026; 18(6): 117582
- URL: https://www.wjgnet.com/1948-5204/full/v18/i6/117582.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v18.i6.117582